These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1160 related articles for article (PubMed ID: 794745)

  • 41. [Intralesional therapy of melanoma metastases with recombinant interferon-beta].
    Fierlbeck G; d'Hoedt B; Stroebel W; Stutte H; Bogenschütz O; Rassner G
    Hautarzt; 1992 Jan; 43(1):16-21. PubMed ID: 1612904
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Immunotherapy with BCG and mycobacterial fractions and its use in bronchogenic carcinoma (author's transl)].
    Brehmer W; Huckauf H; Ribi E
    Prax Klin Pneumol; 1979 Apr; 33 Suppl 1():358-65. PubMed ID: 461310
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Interferon therapy in malignant melanoma].
    Stadler R; Garbe C
    Z Hautkr; 1990 May; 65(5):504-7. PubMed ID: 1696048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Malignant melanoma and immunotherapy.
    Br Med J; 1976 Oct; 2(6040):831-2. PubMed ID: 791438
    [No Abstract]   [Full Text] [Related]  

  • 45. [Immunotherapy of malignant melanoma].
    Adler A
    Harefuah; 1986 Jul; 111(1-2):11-7. PubMed ID: 3781371
    [No Abstract]   [Full Text] [Related]  

  • 46. [Intralesion BCG vaccine therapy in cutaneous melanoma metastasis].
    Wolf M; Menzel W
    Dermatol Monatsschr; 1978 Sep; 164(9):671-2. PubMed ID: 710658
    [No Abstract]   [Full Text] [Related]  

  • 47. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
    Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
    Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Application of viable bacille Calmette-Guérin topically as a potential therapeutic modality in condylomata acuminata: a placebo-controlled study.
    Metawea B; El-Nashar AR; Kamel I; Kassem W; Shamloul R
    Urology; 2005 Feb; 65(2):247-50. PubMed ID: 15708031
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA; Rapp HJ
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Melanoma: the management of local recurrence and in-transit metastasis.
    Couture J
    Can J Surg; 1982 Nov; 25(6):698-700. PubMed ID: 7139431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.
    Mastrangelo MJ; Bellet RE; Berkelhammer J; Clark WH
    Cancer; 1975 Oct; 36(4):1305-8. PubMed ID: 1175129
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of malignant skin tumours with oral administration of BCG in enteric-coated capsules.
    Ishihara K; Ikeda S; Arai E; Sawada T
    Dev Biol Stand; 1986; 58 ( Pt A)():465-74. PubMed ID: 3596050
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical and molecular insights into BCG immunotherapy for melanoma.
    Kremenovic M; Schenk M; Lee DJ
    J Intern Med; 2020 Dec; 288(6):625-640. PubMed ID: 32128919
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Histologic changes in the human skin melanoma after intratumorous treatment with BCG.
    Svejda J; Mechl Z; Sopková B; Foukal T
    Neoplasma; 1979; 26(2):215-21. PubMed ID: 471128
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.
    McKhann CF; Hendrickson CG; Spitler LE; Gunnarsson A; Banerjee D; Nelson WR
    Cancer; 1975 Feb; 35(2):514-20. PubMed ID: 234291
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.
    Krown SE; Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Huvos AG; Oettgen HF
    Cancer; 1978 Dec; 42(6):2648-60. PubMed ID: 728866
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical and histologic correlation of melanoma regression after intralesional BCG therapy: a case report.
    Mastrangelo MJ; Kim YH; Bornstein RS; Chee DO; Sulit HL; Yarbro JW; Prehn RT
    J Natl Cancer Inst; 1974 Jan; 52(1):19-24. PubMed ID: 4590009
    [No Abstract]   [Full Text] [Related]  

  • 59. Re-inventing intratumoral immunotherapy for melanoma.
    Triozzi PL; Tuthill RJ; Borden E
    Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
    de la Monte SM; Hutchins GM
    Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.